Idarucizumab: A Review as a Reversal Agent for Dabigatran

@article{Syed2016IdarucizumabAR,
  title={Idarucizumab: A Review as a Reversal Agent for Dabigatran},
  author={Yahiya Y. Syed},
  journal={American Journal of Cardiovascular Drugs},
  year={2016},
  volume={16},
  pages={297-304}
}
  • Yahiya Y. Syed
  • Published 2016
  • Medicine
  • American Journal of Cardiovascular Drugs
  • Idarucizumab (Praxbind®), a humanized monoclonal antibody, is a specific reversal agent for the direct oral thrombin inhibitor dabigatran, available as its prodrug dabigatran etexilate (Pradaxa®). Idarucizumab is approved in several countries (including the USA, the EU, Canada and Australia) for use in adult patients on dabigatran when the reversal of its anticoagulant effects is required for emergency surgery/procedures or in the event of life-threatening or uncontrolled bleeding. In the… CONTINUE READING
    7 Citations

    References

    SHOWING 1-10 OF 29 REFERENCES
    Idarucizumab for Dabigatran Reversal.
    • 996
    • Highly Influential
    • PDF
    Dabigatran Etexilate
    • K. P. Garnock-jones
    • Medicine
    • American journal of cardiovascular drugs : drugs, devices, and other interventions
    • 2011
    • 27
    Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
    • 123
    • Highly Influential
    • PDF
    A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
    • 206
    • Highly Influential
    • PDF